◀ Back to ST3GAL4

KNG1 — ST3GAL4

Text-mined interactions from Literome

Arbin et al., Br J Pharmacol 2000 (Diabetes Mellitus, Experimental) : The role of the kinin-nitric oxide ( NO ) pathway was assessed by ( 1 ) using pre-treatments : a bradykinin ( BK ) B2 receptor antagonist ( Hoe-140, 300 microg kg ( -1 ) ), a NO-synthase inhibitor ( N ( omega ) -nitro-L-arginine methyl ester, L-NAME, 10 mg kg ( -1 ) ), a kininase I inhibitor ( DL-2-mercaptomethyl-3-guanidinoethylthiopropanoic acid, MGTA, 10 mg kg ( -1 ) +20 mg kg ( -1 ) 20 min ( -1 ) infusion ) and ( 2 ) comparing the effects in STZ induced diabetic ( STZ-BN ) and control Brown-Norway kininogen-deficient ( C-BN ) rats
Tschöpe et al., Int Immunopharmacol 2003 (Diabetes Mellitus, Experimental...) : STZ led to a reduction of renal KLK and ACE activity and NEP expression and to a three-fold increase of urinary BK excretion and renal kininogen expression